Co-Development, Co-Promote and Profit Share Agreement Sample Contracts

Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. FIRST AMENDMENT TO AMENDED AND RESTATED...

Co-Development, Co-Promote and Profit Share Agreement • September 9th, 2021 • 2seventy Bio, Inc. • Pharmaceutical preparations

• Contract Type
  Co-Development, Co-Promote and Profit Share Agreement
• Filed
  September 9th, 2021
• Company
  2seventy Bio, Inc.
• Industry
  Pharmaceutical preparations

This First Amendment to Amended and Restated Co-Development, Co-Promote and Profit Share Agreement (this “First Amendment”) is entered into as of May 8, 2020 (the “First Amendment Effective Date”) by and between bluebird bio, Inc., a Delaware corporation having its principal place of business at 60 Binney Street, Cambridge, MA 02142 (“Bluebird”) and Celgene Corporation, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 86 Morris Avenue, Summit, NJ 07901 (“Celgene Corp”), with respect to all rights and obligations under the CCPS Agreement (as defined below) in the United States (subject to Section 18.18 of the CCPS Agreement), and Celgene European Investment Company LLC, a limited liability company organized under the laws of Delaware and having a principal place of business at Route de Perreux 1, 2017 Boudry, Switzerland, with respect to all rights and obligations under the CCPS Agreement outside of the United States (subject to Sectio

EX-10.20 2 blue-ex1020_259.htm EX-10.20

Co-Development, Co-Promote and Profit Share Agreement • May 5th, 2020 • New York

• Contract Type
  Co-Development, Co-Promote and Profit Share Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED

SECOND AMENDMENT TO

Co-Development, Co-Promote and Profit Share Agreement • August 14th, 2023 • 2seventy Bio, Inc. • Pharmaceutical preparations

• Contract Type
  Co-Development, Co-Promote and Profit Share Agreement
• Filed
  August 14th, 2023
• Company
  2seventy Bio, Inc.
• Industry
  Pharmaceutical preparations

Amended and Restated Co-Development, Co-Promote and Profit Share Agreement by and between bluebird bio, Inc. and Celgene Corporation and Celgene European Investment Company LLC March 26, 2018

Co-Development, Co-Promote and Profit Share Agreement • September 9th, 2021 • 2seventy Bio, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Co-Development, Co-Promote and Profit Share Agreement
• Filed
  September 9th, 2021
• Company
  2seventy Bio, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Amended and Restated Co-Development, Co-Promote and Profit Share Agreement (this “CCPS Agreement”), dated as of March 26, 2018 (the “CCPS Agreement Effective Date”), is made by and between bluebird bio, Inc., a Delaware corporation (“Bluebird”), and Celgene Corporation, a Delaware corporation (“Celgene Corp”), with respect to all rights and obligations under this CCPS Agreement in the United States (subject to Section 18.18), and Celgene European Investment Company LLC, a Delaware limited liability company, with respect to all rights and obligations under this CCPS Agreement outside of the United States (subject to Section 18.18) (“Celgene Europe” and together with Celgene Corp, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties.”